W.L. Gore & Associates announced that it enrolled the first U.S. patient in a clinical trial for its Viafort vascular stent.
Gore aims to evaluate Viafort for the treatment of symptomatic inferior vena cava (IVC) obstruction with or without iliofemoral obstruction.
The prospective, non-randomized, multi-center, single-arm study includes five-year follow-up. Dr. Kush Desai of Northwestern University Feinberg School of Medicine enrolled the first U.S. patient.